Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Review Article

What is the Role of Cangrelor in Patients Undergoing PCI?

Author(s): Michal Droppa and Tobias Geisler*

Volume 16, Issue 5, 2018

Page: [484 - 489] Pages: 6

DOI: 10.2174/1570161116666180117105834

Price: $65

Abstract

Dual antiplatelet therapy with aspirin and oral P2Y12-receptor inhibitors prevents ischemic events in patients undergoing Percutaneous Coronary Intervention (PCI). However, oral administration of antiplatelet drugs cause delay of onset of platelet inhibition in P2Y12-inhibitor naïve patients. Cangrelor is a novel P2Y12-receptor inhibitor which is administrated intravenously and thus allows immediate antiplatelet inhibition during PCI. Due to its unique pharmacokinetics with fast onset of platelet inhibition and very short plasma half-life it allows effective and controllable periprocedural platelet inhibition. It could reduce short-term ischemic events in large randomized clinical trials. The present article reviews the available evidence and application on cangrelor use in clinical practice.

Keywords: Cangrelor, P2Y12-receptor inhibitors, platelet inhibition, coronary artery disease, acute coronary syndrome, percutaneous coronary intervention.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy